Manfred Bodenlenz, Christian Dragatin, Lisa Liebenberger, Bernd Tschapeller, Beate Boulgaropoulos, Thomas Augustin, Reingard Raml, Christina Gatschelhofer, Nathalie Wagner, Khaled Benkali, Francois Rony, Thomas Pieber, Frank Sinner
PURPOSE: To evaluate the kinetics of topically applied clobetasol-17-propionate (CP-17) in lesional and non-lesional psoriatic skin when released from a commercially available low-strength cream using in vivo dermal open-flow microperfusion (dOFM). METHODS: Twelve patients received Dermovate® cream (CP-17, 0.05%) on small lesional and non-lesional skin test sites for 14 days, once daily. On day 1 and 14, dOFM samples were continuously taken in the dermis for 24 h post-dose and analyzed by LC-MS/MS...
September 2016: Pharmaceutical Research